SearchResearch productsPartner with us中文
English

REBUILD · READ · RECTIFY

Developing therapeutics and diagnostics through migrasome biology

Engineered delivery, disease information analysis and targeted regulation: three platforms advancing the translation of migrasome biology.

Explore the three platformsView the R&D pipeline
Rebuild

Engineered delivery platform

Delivering larger, more complex medicines into target cells

We produce engineered migrasomes through induced spatial displacement, combining a large cargo space, modifiable cell-derived membranes and membrane-fusion release to expand delivery options for complex payloads.

  • Large cargo space
  • Targeted, efficient release
  • Biocompatibility
  • Readily modified membranes
Concept illustration of engineered migrasomes and their production
Explore Rebuild: principles and experimentsClose Rebuild details

Four modules enable endogenous loading in producer cells

A migrasome generation module, therapeutic cargo, a loading enhancement module and a membrane-fusion protein are introduced into producer cells. Large payloads are loaded endogenously, followed by induced relative spatial displacement to form engineered migrasomes.

Four-module endogenous loading and exogenous loading of engineered migrasomes
  1. 01Four-module engineering
  2. 02Endogenous loading
  3. 03Displacement-induced production
  4. 04Target recognition and fusion release

Large cargo space for complex biological payloads

  • Ultra-long mRNA
  • Large gene editors with multiple gRNAs
  • Mitochondria

Engineering advantages for complex cargo delivery

In vitro transcription (IVT), purification and LNP packaging of ultra-long mRNA present multiple engineering challenges. RNA impurities may increase immune stimulation, while encapsulation and particle structure affect effective delivery. FusoMig combines endogenous loading in producer cells, large cargo space and membrane-fusion release to provide key engineering advantages for ultra-long nucleic acids and complex payloads.

An efficient, customizable targeted delivery system

Efficient delivery to primary cells

NCLipo3000 +
Cre plasmid		FusoMig-Cre
BrightfieldNC, Brightfield, 100 μmLipo3000 + Cre plasmid, Brightfield, 100 μmFusoMig-Cre, Brightfield, 100 μm
GFPNC, GFP, 100 μmLipo3000 + Cre plasmid, GFP, 100 μmFusoMig-Cre, GFP, 100 μm
tdTomatoNC, tdTomato, 100 μmLipo3000 + Cre plasmid, tdTomato, 100 μmFusoMig-Cre, tdTomato, 100 μm
Delivery efficiency0%10%95%
FusoMig delivers functional cargo to primary cells.

Selective delivery to the muscle layer

FusoMig-CreFusoMig control
ZsGreenFusoMig-Cre, ZsGreen, 50 μmFusoMig control, ZsGreen, 50 μm
tdTomatoFusoMig-Cre, tdTomato, 50 μmFusoMig control, tdTomato, 50 μm
After local injection, FusoMig can selectively enter the muscle layer.

Cytosolic delivery of the full payload through membrane fusion

FusoMig delivers organelles through membrane fusion

Merged channelsFusoMig mitochondria · greenRecipient mitochondria · red
Read

Disease information analysis platform

Enriching migrasomes to read key disease signals

Our proprietary isolation, purification, identification and target discovery system enriches migrasomes from diverse tissues and body fluids, revealing previously underexplored disease information for diagnostic development and target discovery.

  • Selective enrichment
  • Diverse tissues and body fluids
  • Diagnostics and target discovery
Concept illustration of disease information analysis using migrasomes
Explore Read: principles and experimentsClose Read details

A new organelle means previously unexplored information

Complex backgrounds in blood and tissue can obscure key signals. Our unique platform first enriches and identifies migrasomes, then reads the molecular information they carry, focusing disease research on this specific biological component.

DIC research samples and controls progress through migrasome isolation, multi-omics analysis and database-led diagnostic and target discovery research
  1. 01DIC research samples and controls
  2. 02Migrasome isolation and enrichment
  3. 03Multi-omics analysis
  4. 04Diagnostic research and target discovery

Marker protein identification of isolated fractions

A proprietary isolation and identification system provides the foundation for migrasome information analysis.

Migrasome morphology and marker protein profiles help identify isolated fractions for subsequent molecular analysis and target discovery.

  • Cancer
  • Inflammation
  • Infection
  • Coagulation
  • Autoimmune disease
Marker protein immunoblots of cell body, migrasome, retractosome and small EV fractions
Rectify

Migrasome regulation and drug discovery platform

Developing medicines that target migrasome disease mechanisms

Our proprietary research into migrasome formation and disease mechanisms identifies actionable targets and supports the development of modulators, opening a new biological dimension for therapeutic discovery.

  • Mechanism-driven discovery
  • Actionable targets
  • Modulator development
Concept illustration of migrasome regulation across disease areas
Explore Rectify: principles and experimentsClose Rectify details

Regulating migrasomes in both directions

We investigate selective inhibition or promotion of migrasome formation and function according to their roles in disease, identifying actionable targets for innovative medicines.

English translation of the original company BP diagram of bidirectional migrasome regulation

Experimental observations of migrasome regulation

Specifically regulate migrasomes by targeting the mechanisms of their formation.

Inhibitor experiments in L929 and NRK cells and quantification of migrasomes on retraction fibres, with original groups, scale bars and statistics

Advancing migrasome translation together

Explore R&D partnerships in disease information, regulatory targets and engineered delivery.

Discuss a partnershipView the R&D pipeline